project . 2021 - 2024 . On going

DIMEvAR

Impact of medical drugs on the evolution of human microbiome function and antimicrobial resistance development
Open Access mandate for Publications and Research Data European Commission
  • Funder: European CommissionProject code: 101026763 Call for proposal: H2020-MSCA-IF-2020
  • Funded under: H2020 | MSCA-IF-EF-CAR Overall Budget: 262,210 EURFunder Contribution: 262,210 EUR
  • Status: On going
  • Start Date
    01 Apr 2021
    End Date
    31 Mar 2024
  • Detailed project information (CORDIS)
Description
The human gastrointestinal tract harbors trillions of microbes, known as the gut microbiota. This microbial community helps modulating developmental, immunological, and metabolic functions of the human host and it plays an important role in medicinal drug response. Several works showed the bidirectional relationship between the gut microbiota and drugs. Medication modifies microbiome composition both in vitro and in the human gut. Further, commonly used drugs influence the microbiome metabolic functions and increase the abundance of antimicrobial resistance (AMR) genes in human cohort studies, suggesting that non-antibiotic drugs could contribute to the emergenc...
Description
The human gastrointestinal tract harbors trillions of microbes, known as the gut microbiota. This microbial community helps modulating developmental, immunological, and metabolic functions of the human host and it plays an important role in medicinal drug response. Several works showed the bidirectional relationship between the gut microbiota and drugs. Medication modifies microbiome composition both in vitro and in the human gut. Further, commonly used drugs influence the microbiome metabolic functions and increase the abundance of antimicrobial resistance (AMR) genes in human cohort studies, suggesting that non-antibiotic drugs could contribute to the emergenc...
Any information missing or wrong?Report an Issue